Acute rejection timing in the first post-transplant year is not associated with incident cardiac allograft vasculopathy
Abstract Heart transplantation (HT) is the durable therapy for end-stage heart failure (HF). Despite advances in immunosuppression, cardiac allograft vasculopathy (CAV) remains a leading cause of late graft failure and mortality in the modern era. Prior studies have established donor age and immunological phenomena, such as acute cellular rejection (ACR), antibody-mediated rejection (AMR), and development of donor-specific antibodies (DSAs) as risk factors for CAV 1-5 . However, it remains unclear whether acute rejection (AR) that occurs early post-HT, when individuals experience the highest degree of immunosuppression, reflects higher baseline immune activity and confers a higher risk of future CAV compared to later AR, when immunosuppression is minimized. We therefore examined whether AR occurring during pre-specified early and intermediate intervals compared to those who did not experience AR in the first post-HT year was associated with future CAV among recipients without CAV at 1 year.
Authors
- Aseem Utrankar
- Benjamin French
- Nelson Chow
- Quinn S. Wells (ORCID: https://orcid.org/0009-0009-4141-1520)
- Hasan K. Siddiqi
- Eric Farber-Eger
- Jonathan N. Menachem
- Aniket S. Rali
- Blake Butler
- Shi Huang
- Kelly H. Schlendorf
- Kaushik Amancherla
Institutions
- Harvard University (US)
- Vanderbilt University (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Journal of Cardiac Failure - Intersections
- Published
- 2026-09-01
- DOI
- https://doi.org/10.1016/j.yjcafi.2026.08.007
- Primary Topic
- Transplantation: Methods and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bill and Melinda Gates Foundation
- American Heart Association
- National Institutes of Health